AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 41 min read$BSX

Boston Scientific (BSX) Receives a Buy from RBC Capital

RBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. The stock closed at $43.23. The Street's consensus is Strong Buy, with a $58.58 average target, implying 35.51% upside. Boston Scientific reported Q2 revenue of $5.44B and net profit of $907M, up from $5.06B and $793M last year. Insider sentiment is positive, with recent purchases by directors.

Original reporting
theglobeandmail.com
Published Oct 4, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Boston Scientific (BSX) Receives a Buy from RBC Capital — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$BSXBullishLow
01

Why it matters

Analyst maintains Buy with a higher price target, suggesting incremental upside.

02

Market read

The article provides a modest bullish signal for BSX but adds little new material.

03

What to watch

No new product launches or guidance changes accompany the rating.

Relevance 4/10Novelty 2/10Timing: none

Background

Boston Scientific recently reported Q2 earnings with modest revenue and profit growth.

Company-level read

Ticker impact

$BSXBullishMedium confidence
Context

RBC Capital maintained a Buy rating on Boston Scientific and set a $70 price target, citing recent earnings and insider buying.

Expected impact

potential modest upside as investors price in the higher target.

Evidence & confidence

The rating is unchanged but the $70 target is above current price, and insider buying adds support.

Market effects

Sector

Reinforces positive outlook for the broader medical device sector.

Regional

Limited to U.S. healthcare investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The rating is unchanged; investors may view the target as overly optimistic given modest earnings growth.

Key entities

  • Company
    Boston Scientific

    Medical device manufacturer (ticker BSX).

  • Analyst Firm
    RBC Capital

    Maintained Buy rating and set $70 target.

Read at source← All news

Related articles

OCT 7
$BSXMed

Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructure

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.

gurufocus.com2 min
OCT 1
$BSXHigh

FDA Approves SpaceOAR Flex Hydrogel Rectal Spacer

FDA cleared Boston Scientific's SpaceOAR Flex Hydrogel, a rectal spacer for prostate cancer radiation therapy. The company claims it offers simpler setup and flexible delivery. Interim trial data showed 92.4% of patients had a 25% reduction in rectal radiation dose. Boston Scientific funded the study.

renalandurologynews.com2 min
SEP 30
$BSXMedAI 8/10

Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

Boston Scientific reported mixed Q2 2026 results, with Endoscopy sales up 7% YoY and Neuromodulation up 12%, but Urology underperforming. The company received FDA clearance for RIVOS and plans key launches to boost Urology growth. BSX shares fell 30.2% over six months, trading at a forward P/S ratio of 2.89. Medtronic and Teleflex also reported recent developments.

zacks.com2 min